Abstract
We aimed to evaluate the clinical efficacy of the single-stage posterior surgical treatment for patients of lumbar brucella spondylitis combined with spondylolisthesis. In this study, we performed a retrospective analysis of 16 patients with lumbar brucellosis spondylitis combined with spondylolisthesis from January 2015 to January 2019. All patients underwent single-stage posterior lumbar debridement, reduction, interbody fusion, and instrumentation. Preoperative and postoperative of the visual analog scale (VAS), the Japanese orthopedic association scores (JOA), the Oswestry disability index (ODI), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) were compared. In addition, the spondylolisthesis reduction rate, reduction loss rate, interbody fusion rate, and complication rate were recorded. VAS, JOA, ODI, ESR, and CRP were conducted with repeated analysis of variance data at different follow-ups. The postoperative follow-up was 12 to 36 months, with an average of (25.0±8.1) months. VAS, JOA, ODI, ESR, and CRP were significantly better at two-week and one-year follow-up than preoperative results (P=0.000, respectively). In addition, one year after the operation, VAS, JOA, ODI, ESR, and CRP showed a significant improvement (P=0.000, respectively). The average spondylolisthesis reduction in two weeks after operation was (91.2±6.7) %, and the median reduction loss rate in one year after operation was 8.0 (5.0,9.8) %. At the last follow-up, all patients achieved interbody fusion, no loosening and fracture of instrumentation were found, and no recurrence happened. Single-stage posterior operation for lumbar debridement, reduction, interbody fusion, and instrumentation is beneficial for treating lumbar brucellosis spondylitis combined with spondylolisthesis. Furthermore, the reconstruction of spinal stability may relieve pain, heal lesions, and improve patients’ living.
Competing Interest Statement
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Clinical Trial
N
Clinical Protocols
N
Funding Statement
Yao Zhang?This research was funded by the science foundation of Beijing Ditan Hospital Capital Medical University (No.DTQL201803).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval from the Ethics Committee of Beijing Ditan Hospital, Capital Medical University was obtained for this study. Each author certifies that all investigations were conducted in conformity with ethical principles.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Not Applicable
Data Availability
All relevant data are within the manuscript and its Supporting Information files.
N
